SCM
AZN icon

Suffolk Capital Management’s AstraZeneca AZN Stock Holding History

Suffolk Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-179,560
Closed -$12.2M – 126
2017
Q3 		$12.2M Sell
179,560
-5,110
-3% -$323K 1.61% 36
2017
Q2 		$12.6M Buy
+184,670
New +$12.1M 1.66% 24

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Suffolk Capital Management's AZN Position: Q4 2017 in Review

Suffolk Capital Management sold out of AstraZeneca (AZN) in Q4 2017, closing a stake of 179,560 shares — an estimated $12.2M sold.

Suffolk Capital Management first reported a position in AZN in Q2 2017 and held it in 2 quarters. The position peaked at $12.6M in Q2 2017. 503 funds tracked by Wall St. Rank hold AZN as of Q4 2017.

  • Suffolk Capital Management reported no remaining AstraZeneca position as of Q4 2017 after selling out during the quarter.
  • Suffolk Capital Management sold 179,560 AstraZeneca shares in Q4 2017, an estimated $12.2M.
  • Suffolk Capital Management first reported a position in AstraZeneca in Q2 2017 and held it in 2 quarters.
  • Suffolk Capital Management's AstraZeneca position peaked at $12.6M in Q2 2017.
  • 503 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2017.

Based on Suffolk Capital Management's 13F filing for Q4 2017, filed 9 Feb 2018.